

*Agenda:* To review and evaluate grant applications.

*Place:* Video Assisted Meeting.

*Contact Person:* Leonid V. Tsap, Ph.D., Scientific Review Officer, Extramural Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 500, Bethesda, MD 20892-7968, 301-827-7077, [tsapl@mail.nih.gov](mailto:tsapl@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: November 2, 2020.

**Ronald J. Livingston, Jr.,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-24669 Filed 11-5-20; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Aging; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Clinical trials for COVID 19 management in older individuals.

*Date:* December 11, 2020.

*Time:* 10:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, (301) 496-9374, [grimaldim2@mail.nih.gov](mailto:grimaldim2@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: November 2, 2020.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-24615 Filed 11-5-20; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Heart, Lung and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), both of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive patent license to Inversago Pharma Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before November 23, 2020 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Anna Solowiej, Ph.D., J.D., Senior Licensing and Patenting Manager, NHGRI Technology Transfer Office; Telephone (301) 435-7791; Email: [anna.solowiej@nih.gov](mailto:anna.solowiej@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma Inc.:

NIH ref No.	Patent No. or application No.	Issue date	Filing date	Title
E-282-2012-0-US-01	61/725,949		November 13, 2012	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-PCT-02	PCT/US2013/069686		November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-03	9,765,031	September 19, 2017	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CA-04	2889697		April 27, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-EP-05	13802153.0	TBD	June 01, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CH-12	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-DE-13	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-FR-14	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-GB-15	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IE-16	13802153.0	TBD	November 12, 2013	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IN-06	3733/DELNP/2015		May 1, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-JP-07	6272626	January 12, 2018	May 11, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CN-08	ZL201380069389.9	August 20, 2019	July 3, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-09	10,683,270	June 16, 2020	August 10, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-10	15/674,333	TBD (application allowed)	August 10, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-11	16/870,093		May 8, 2020	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-01	62/171,179		June 4, 2015	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-PCT-02	PCT/US2016/035291		June 1, 2016	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-EP-05	16/28547.7		June 1, 2016	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-08	15/579,123		December 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-09	16/438,850		June 12, 2019	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-US-01	15/061,829		March 4, 2016	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-PCT-02	PCT/US2017/020250		March 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-CN-03	2017800118698		March 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-EP-04	17711443.6		March 1, 2017	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-01	61/991,333		May 9, 2014	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-PCT-02	PCT/US2015/029946		May 8, 2015	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-AU-03	2015255765		November 7, 2016	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CA-04	2948349		May 8, 2015	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CN-05	201580028788.X	February 7, 2020	May 8, 2015	Cannabinoid Receptor Mediating Compounds.